FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm
Posted on10 Jun 2021
Tagsaducanumab, Aduhelm, Biogen, Eisai, global pharma licensing deal, monoclonal antibody, Neurimmune, pharma deal
Comments0
USFDA approved Aduhelm (aducanumab) for the treatment of Alzheimer disease. Alzheimer’s drug Aduhelm is research molecule of Neurimmune. Neurimmune licensed its antibody... Read More
Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
Global pharmaceutical company, Sanofi will acquire a clinical-stage biopahrmaceutical company Kymab. Sanofi will acquire Kymab for an upfront payment of approximately $1.1... Read More
AstraZeneca – Alexion $39 billion deal
Posted on15 Dec 2020
Tagsacquisition in pharma, global pharma deals, largest ever pharma deal, monoclonal antibody, pharma deal, ravulizumab, Soliris, Ultomiris
Comments0
AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for $39 billion to bolster its positions in immunology and rare diseases. Alexion... Read More
Case Study – Inmazeb: USFDA Approval of first ebola medicine
U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a combination of three monoclonal antibodies, as the first FDA-approved treatment... Read More
AbbVie’s Elezanumab receives US FDA orphan drug and fast track designations
Posted on30 Sep 2020
Comments0
AbbVie announced that the US Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an... Read More
Regeneron, Sanofi initiates clinical trial in Kevzara to treat COVID-19
Regeneron Pharmaceuticals and Sanofi have started a clinical programme evaluating Kevzara (sarilumab) in patients hospitalized with severe coronavirus (COVID-19) infection. Kevzara is... Read More
Pfizer launched Zirabev, Ruxience, Trazimera biosimilar in US
Posted on29 Jan 2020
TagsBevacizumab, Biosimilar, MAB, monoclonal antibody, pfizer, Rituximab, Ruxience, trastuzumab, Trazimera, Zirabev
Comments0
Pfizer has launched three biosimilars in the U.S. market. Pfizer has priced these biosimilars aggressively to get quick market share. Zirabev Biosimilar... Read More
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab
Posted on17 Jul 2019
Tagscrizanlizumab, MAB, monoclonal antibody, priority review, Priority Review Designation, USFDA Priority Review
Comments0
Novartis announced the US Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) and has granted Priority Review for... Read More
Roche to launch emicizumab (Hemlibra) in India for people with haemophilia A on World Haemophilia Day
Roche announced that emicizumab (Hemlibra) has been approved in India for haemophilia A with factor VIII inhibitors. It is indicated as a... Read More
New Brand Launch: Biocon introducing KRABEVA, a biosimilar Bevacizumab
Posted on24 Nov 2017
Comments0
Biocon Ltd, Asia’s premier biopharmaceuticals company, has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and... Read More